Does the media favor ARQT or ARDX?

In the previous week, Ardelyx had 18 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 19 mentions for Ardelyx and 1 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.42 beat Ardelyx's score of 0.11 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor TARS or ARDX?

In the previous week, Ardelyx had 15 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 19 mentions for Ardelyx and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.33 beat Ardelyx's score of 0.11 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate RGC or ARDX?

Ardelyx has a consensus target price of $13.90, indicating a potential upside of 313.08%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ardelyx 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger earnings and valuation, RGC or ARDX?

Regencell Bioscience has higher earnings, but lower revenue than Ardelyx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Ardelyx $407.32M 2.06 -$61.60M -$0.22 N/A

Does the media prefer RGC or ARDX?

In the previous week, Ardelyx had 18 more articles in the media than Regencell Bioscience. MarketBeat recorded 19 mentions for Ardelyx and 1 mentions for Regencell Bioscience. Ardelyx's average media sentiment score of 0.11 beat Regencell Bioscience's score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate ARDX or MOR?

Ardelyx currently has a consensus target price of $13.90, suggesting a potential upside of 313.08%. Given Ardelyx's stronger consensus rating and higher probable upside, research analysts plainly believe Ardelyx is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, ARDX or MOR?

Ardelyx has higher revenue and earnings than MorphoSys. Ardelyx is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ardelyx $407.32M 2.06 -$61.60M -$0.22 N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is ARDX or MOR more profitable?

Ardelyx has a net margin of -12.35% compared to MorphoSys' net margin of -226.79%. Ardelyx's return on equity of -36.00% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -12.35% -36.00% -10.77% MorphoSys -226.79% -694.31% -22.55%

Is MBX or ARDX more profitable?

MBX Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. MBX Biosciences' return on equity of -26.02% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -26.02% -24.94% Ardelyx -12.35% -36.00% -10.77%

Does the media prefer MBX or ARDX?

In the previous week, Ardelyx had 14 more articles in the media than MBX Biosciences. MarketBeat recorded 19 mentions for Ardelyx and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.24 beat Ardelyx's score of 0.11 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Ardelyx (ARDX) Competitors

$3.34 -0.04 (-1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 +0.02 (+0.45%)

As of 07:30 PM Eastern

Compare

ARDX vs. ARQT, TARS, RGC, MOR, and MBX

Should you buy Ardelyx stock or one of its competitors? Ardelyx's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Regencell Bioscience (RGC), MorphoSys (MOR), and MBX Biosciences (MBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ardelyx compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

58.9% of Ardelyx shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Ardelyx had 18 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 19 mentions for Ardelyx and 1 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.42 beat Ardelyx's score of 0.11 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.43	-$16.14M	$0.21	120.12
Ardelyx	$407.32M	2.06	-$61.60M	-$0.22	N/A

Arcutis Biotherapeutics presently has a consensus price target of $35.57, suggesting a potential upside of 41.02%. Ardelyx has a consensus price target of $13.90, suggesting a potential upside of 313.08%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Arcutis Biotherapeutics has a net margin of 6.15% compared to Ardelyx's net margin of -12.35%. Arcutis Biotherapeutics' return on equity of 15.05% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Ardelyx	-12.35%	-36.00%	-10.77%

Arcutis Biotherapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Ardelyx on 10 of the 17 factors compared between the two stocks.

How does Ardelyx compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ardelyx has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.16	-$66.42M	-$1.09	N/A
Ardelyx	$407.32M	2.06	-$61.60M	-$0.22	N/A

Tarsus Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Ardelyx's net margin of -12.35%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Ardelyx	-12.35%	-36.00%	-10.77%

In the previous week, Ardelyx had 15 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 19 mentions for Ardelyx and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.33 beat Ardelyx's score of 0.11 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals presently has a consensus price target of $100.86, indicating a potential upside of 37.03%. Ardelyx has a consensus price target of $13.90, indicating a potential upside of 313.08%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Tarsus Pharmaceuticals beats Ardelyx on 9 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Ardelyx had 18 more articles in the media than Regencell Bioscience. MarketBeat recorded 19 mentions for Ardelyx and 1 mentions for Regencell Bioscience. Ardelyx's average media sentiment score of 0.11 beat Regencell Bioscience's score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Regencell Bioscience has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Regencell Bioscience's return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Ardelyx	-12.35%	-36.00%	-10.77%

Regencell Bioscience has higher earnings, but lower revenue than Ardelyx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Ardelyx	$407.32M	2.06	-$61.60M	-$0.22	N/A

Ardelyx has a consensus target price of $13.90, indicating a potential upside of 313.08%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Ardelyx beats Regencell Bioscience on 9 of the 14 factors compared between the two stocks.

How does Ardelyx compare to MorphoSys?

Ardelyx (NASDAQ:ARDX) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Ardelyx had 19 more articles in the media than MorphoSys. MarketBeat recorded 19 mentions for Ardelyx and 0 mentions for MorphoSys. Ardelyx's average media sentiment score of 0.11 beat MorphoSys' score of 0.00 indicating that Ardelyx is being referred to more favorably in the media.

Company	Overall Sentiment
Ardelyx	Neutral
MorphoSys	Neutral

Ardelyx currently has a consensus target price of $13.90, suggesting a potential upside of 313.08%. Given Ardelyx's stronger consensus rating and higher probable upside, research analysts plainly believe Ardelyx is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ardelyx has a net margin of -12.35% compared to MorphoSys' net margin of -226.79%. Ardelyx's return on equity of -36.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
MorphoSys	-226.79%	-694.31%	-22.55%

Ardelyx has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Ardelyx has higher revenue and earnings than MorphoSys. Ardelyx is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	2.06	-$61.60M	-$0.22	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Ardelyx beats MorphoSys on 14 of the 17 factors compared between the two stocks.

How does Ardelyx compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Ardelyx has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Ardelyx	$407.32M	2.06	-$61.60M	-$0.22	N/A

MBX Biosciences has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

58.9% of Ardelyx shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MBX Biosciences currently has a consensus price target of $83.89, indicating a potential upside of 43.98%. Ardelyx has a consensus price target of $13.90, indicating a potential upside of 313.08%. Given Ardelyx's higher possible upside, analysts clearly believe Ardelyx is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Ardelyx had 14 more articles in the media than MBX Biosciences. MarketBeat recorded 19 mentions for Ardelyx and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.24 beat Ardelyx's score of 0.11 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

MBX Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. MBX Biosciences' return on equity of -26.02% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Ardelyx	-12.35%	-36.00%	-10.77%

Summary

Ardelyx beats MBX Biosciences on 9 of the 15 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$842.25M	$12.27B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.54%	16.76%
P/E Ratio	-15.18	794.62	273.67	26.04
Price / Sales	2.04	755.06	611.82	91.49
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	4.84	10.46	10.92	6.30
Net Income	-$61.60M	$2.83B	$3.50B	$361.43M
7 Day Performance	-2.34%	-1.65%	-2.11%	-1.67%
1 Month Performance	-12.11%	-5.77%	-6.34%	-3.94%
1 Year Performance	-36.38%	-3.80%	8.81%	2.77%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	2.8647 of 5 stars	$3.34 -1.2%	$13.90 +316.2%	-36.9%	$842.25M	$407.32M	N/A	489	Trending News
ARQT Arcutis Biotherapeutics	3.8194 of 5 stars	$27.33 +1.5%	$35.57 +30.2%	+28.0%	$3.38B	$376.07M	130.15	354
TARS Tarsus Pharmaceuticals	3.1793 of 5 stars	$76.81 +1.5%	$100.86 +31.3%	+31.6%	$3.32B	$451.36M	N/A	50
RGC Regencell Bioscience	0.2791 of 5 stars	$6.20 +0.5%	N/A	-60.0%	$3.05B	N/A	N/A	10	News Coverage
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. ARQT, TARS, RGC, MOR, and MBX

How does Ardelyx compare to Arcutis Biotherapeutics?

Summary

How does Ardelyx compare to Tarsus Pharmaceuticals?

Summary

How does Ardelyx compare to Regencell Bioscience?

Summary

How does Ardelyx compare to MorphoSys?

Summary

How does Ardelyx compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. ARQT, TARS, RGC, MOR, and MBX

How does Ardelyx compare to Arcutis Biotherapeutics?

Do institutionals & insiders hold more shares of ARQT or ARDX?

Does the media favor ARQT or ARDX?

Which has stronger earnings and valuation, ARQT or ARDX?

Do analysts recommend ARQT or ARDX?

Is ARQT or ARDX more profitable?

Which has more volatility and risk, ARQT or ARDX?

Summary

How does Ardelyx compare to Tarsus Pharmaceuticals?

Do insiders & institutionals believe in TARS or ARDX?

Which has stronger earnings and valuation, TARS or ARDX?

Which has more volatility and risk, TARS or ARDX?

Is TARS or ARDX more profitable?

Does the media favor TARS or ARDX?

Do analysts recommend TARS or ARDX?

Summary

How does Ardelyx compare to Regencell Bioscience?

Does the media prefer RGC or ARDX?

Do institutionals & insiders believe in RGC or ARDX?

Which has more risk & volatility, RGC or ARDX?

Is RGC or ARDX more profitable?

Which has stronger earnings and valuation, RGC or ARDX?

Do analysts rate RGC or ARDX?

Summary

How does Ardelyx compare to MorphoSys?

Does the media refer more to ARDX or MOR?

Do analysts rate ARDX or MOR?

Is ARDX or MOR more profitable?

Which has more volatility & risk, ARDX or MOR?

Which has preferable valuation and earnings, ARDX or MOR?

Do insiders & institutionals have more ownership in ARDX or MOR?

Summary

How does Ardelyx compare to MBX Biosciences?

Which has higher earnings & valuation, MBX or ARDX?

Which has more risk and volatility, MBX or ARDX?

Do institutionals & insiders believe in MBX or ARDX?

Do analysts recommend MBX or ARDX?

Does the media prefer MBX or ARDX?

Is MBX or ARDX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools